Businesswire·2025-12-29 14:00Core Insights - CEL-SCI Corporation reported financial results for the fiscal year ending September 30, 2025, highlighting significant clinical and corporate developments [1] Financial Performance - The company disclosed its financial results, which include revenue figures and expenses for the fiscal year [1] - Specific financial metrics such as net income or loss, operating expenses, and cash reserves were detailed [1] Clinical Developments - Key clinical developments were outlined, including progress in ongoing trials and any new data related to Multikine [1] - The company may have announced milestones achieved in its clinical research efforts [1] Corporate Developments - Corporate strategies and initiatives were discussed, potentially including partnerships, collaborations, or changes in management [1] - Future outlook and plans for the upcoming fiscal year were also mentioned, indicating the company's direction [1]